Good morning, one and all. Damian Garde here, filling in for Ed Silverman at Pharmalot’s satellite campus. It is, as you undoubtedly know, the end of yet another working week, which of course means all the assorted indignities of a laboring life will soon fade into the weekend. As always, we hope you have plans to make the most of your reprieve, however brief. In the meantime, please find a few tidbits to get you started this fine Friday. And if you hear anything that raises your eyebrow, do let us know.

Sanofi is replacing CEO Olivier Brandicourt with an executive from Novartis, Reuters reports. On Sept. 1, Novartis’s Paul Hudson will take over the French drug maker. Hudson, who joined Novartis in 2016, has led the Swiss company’s pharmaceutical division. Brandicourt will retire after four years in charge of Sanofi.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy